NEW YORK, May 27, 2026, 11:08 EDT
- CapsoVision shares traded modestly higher in light volume while the broader medical-device tape fell.
- The latest company catalyst remains its May 14 first-quarter report, not a fresh release.
- Investors are watching FDA clearance for its AI-assisted reading tool and a planned third-quarter colon-capsule filing.
CapsoVision Inc. shares edged higher in late Wednesday morning trading, outpacing a weaker medical-device sector as investors stayed focused on the company’s pending artificial-intelligence product work rather than its still-thin revenue base.
The stock was up 5 cents, or about 0.8%, at $6.67 in the latest available trade at 10:45 a.m. EDT, with volume of 14,335 shares. The iShares U.S. Medical Devices ETF fell about 1.4%, while the SPDR S&P 500 ETF was little changed.
The move matters because there was no obvious fresh company release behind it. CapsoVision’s news page listed its first-quarter report dated May 14 as the most recent release, putting Wednesday’s trading more in the category of a live market read on old news than a reaction to a new announcement.
CapsoVision said in that report that first-quarter revenue was $2.8 million, stable from a year earlier, while CapsoCam Plus had been used by more than 167,000 patients as of March 31. Chief Executive Johnny Wang cited “continued strength in underlying utilization” and called the expected FDA clearance of the company’s AI-assisted reading feature an “important inflection point.” SEC
The product is aimed at capsule endoscopy, in which a patient swallows a small camera capsule so doctors can inspect the gastrointestinal tract without a standard scope. A 510(k) filing, the U.S. Food and Drug Administration path used to show a device is substantially equivalent to an already cleared product, is expected in the third quarter for CapsoVision’s second-generation CapsoCam Colon program, the company said.
On the earnings call, Senior Vice President of Finance David Garcia said capsule volume was lower because some large orders slipped into April, not because of a pricing push. After StoneX analyst Bruce Jackson asked about pricing and forward buying, Garcia said there was “no price increase.” Asked by Titan PI analyst Kyle Bauser about the FDA status for the AI-assisted reading feature, Wang said there were “no showstoppers to my knowledge.” Investing.com Nigeria
The pressure point remains costs. Gross margin, the share of sales left after production costs, fell to 48% from 54% a year earlier, with the company citing changes in U.S. trade policies and tariffs. Operating expenses rose to $8.4 million, driven mainly by work on new CMOS image sensors under a Canon agreement and clinical-trial activity for CapsoCam Colon.
CapsoVision is also small beside rivals. Its annual filing names Medtronic, IntroMedic, JinShan and Ankon as competitors in capsule-based imaging, and says Medtronic has a first-mover advantage and greater financial resources. It also noted that Ankon, through AnX Robotics, already has an FDA-cleared AI product for small-bowel capsule endoscopy.
But the downside case is plain. CapsoVision’s quarterly filing said there was substantial doubt about its ability to continue as a going concern, meaning it may not be able to keep operating without more outside capital. The company had $17.9 million in cash and cash equivalents at March 31 after a $14 million private placement, a sale of securities to selected investors, but said that cash would not fund operations for at least the next 12 months under its current plan.
For now, the stock is trading on execution. A clean FDA step on AI could help the company argue that CapsoCam Plus is moving from a niche imaging device toward a software-enabled platform. A delay, weak uptake or another margin squeeze would push the debate back to cash burn and financing.
